A股異動丨Kimi概念股獲資金追捧,掌閲科技等多股升停
A股市場Kimi概念股近日火爆,獲資金追捧。其中,華策影視、中廣天擇、掌閲科技升停,九安醫療升超4%,中文在線、深信服升2%。消息面上,3月18日,AI大模型初創企業——月之暗面宣佈在大模型長上下文窗口技術上取得新的突破,Kimi智能助手已支持200萬字超長無損上下文,並於即日起開啟產品“內測”。這距離去年10月,Kimi智能助手正式推出,最高可支持20萬漢字無損上下文輸入,才過去不到半年時間。月之暗面聯合創始人周昕宇表示,在Sora發佈之前月之暗面就已經有多模態方面的研發,目前正在按照固有節奏推進,預計在今年將會有相關產品發佈。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.